Jim Simons Biotechnology

Renaissance Technologies LLC

$70.6 Billion
Q3 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
PRLD Prelude Therapeutics Inc	$55.6M	$728,000 0.0% of portfolio	544,000	Q3 2025 Reduced 6.5%
RARE Ultragenyx Pharmaceutical Inc.	$2.3B	$658,000 0.0% of portfolio	21,900	Q3 2025 Reduced 89.49%
CRTX Cortexyme, Inc.	$70.5M	$604,000 0.0% of portfolio	468,598	Q3 2025 Added 23.38%
AURA Aura Biosciences, Inc.	$162M	$603,000 0.0% of portfolio	97,608	Q3 2025 Reduced 25.8%
FHTX Foghorn Therapeutics Inc.	$182M	$578,000 0.0% of portfolio	118,236	Q3 2025 Added 88.77%
ADAP Adaptimmune Therapeutics PLC	$4.9M	$567,000 0.0% of portfolio	4,054,089	Q3 2025 Added 115.32%
BCAB Bio Atla, Inc.	$32.3M	$552,000 0.0% of portfolio	800,631	Q3 2025 Added 6.15%
STTK Shattuck Labs, Inc.	$83.1M	$505,000 0.0% of portfolio	216,867	Q3 2025 Added 469.2%
ANTX An2 Therapeutics, Inc.	$22.1M	$489,000 0.0% of portfolio	385,597	Q3 2025 Reduced 3.32%
OCGN Ocugen, Inc.	$269M	$473,000 0.0% of portfolio	290,200	Q3 2025 New
SLS Sellas Life Sciences Group, Inc.	$29.4M	$466,000 0.0% of portfolio	291,822	Q3 2025 New
TNGX Tango Therapeutics, Inc.	$680M	$464,000 0.0% of portfolio	55,300	Q3 2025 Reduced 15.57%
ATNM Actinium Pharmaceuticals, Inc.	$32.7M	$461,000 0.0% of portfolio	288,630	Q3 2025 Added 37.77%
RCKT Rocket Pharmaceuticals, Inc.	$240M	$447,000 0.0% of portfolio	137,177	Q3 2025 Reduced 70.27%
LTRN Lantern Pharma Inc.	$37.6M	$438,000 0.0% of portfolio	100,100	Q3 2025 Added 10.49%
LXRX Lexicon Pharmaceuticals, Inc.	$268M	$403,000 0.0% of portfolio	292,400	Q3 2025 New
RNXT Renovo Rx, Inc.	$6.8M	$398,000 0.0% of portfolio	313,550	Q3 2025 Added 24.52%
RLYB Rallybio Corp	$20.6M	$393,000 0.0% of portfolio	714,800	Q3 2025 Added 47.37%
ORMP Oramed Pharmaceuticals Inc.	$92.4M	$384,000 0.0% of portfolio	148,900	Q3 2025 Added 3.26%
GLSI Greenwich Life Sciences, Inc.	$108M	$374,000 0.0% of portfolio	38,400	Q3 2025 Added 40.66%
PEPG Pep Gen Inc.	$112M	$349,000 0.0% of portfolio	75,700	Q3 2025 Added 47.56%
RLMD Relmada Therapeutics, Inc.	$111M	$341,000 0.0% of portfolio	169,700	Q3 2025 Added 13.06%
IMUX Immunic, Inc.	$22.9M	$332,000 0.0% of portfolio	391,653	Q3 2025 Added 196.36%
CNTX Context Therapeutics Inc.	$18.5M	$310,000 0.0% of portfolio	320,127	Q3 2025 Reduced 12.04%
ALXO Alx Oncology Holdings Inc	$52.2M	$301,000 0.0% of portfolio	164,499	Q3 2025 Added 92.62%
CMPX Compass Therapeutics, Inc.	$494M	$296,000 0.0% of portfolio	79,000	Q3 2025 Reduced 64.83%
PDSB Pds Biotechnology Corp	$24.2M	$284,000 0.0% of portfolio	275,861	Q3 2025 Added 161.02%
DRTS Alpha Tau Medical Ltd.	$256M	$279,000 0.0% of portfolio	61,900	Q3 2025 Added 110.54%
AMLX Amylyx Pharmaceuticals, Inc.	$743M	$270,000 0.0% of portfolio	19,900	Q3 2025 Reduced 94.98%
NVCT Nuvectis Pharma, Inc.	$88.1M	$257,000 0.0% of portfolio	42,800	Q3 2025 Reduced 0.47%
NERV Minerva Neurosciences, Inc.	$21.9M	$255,000 0.0% of portfolio	116,500	Q3 2025 Added 4.95%
MNOV Medicinova Inc	$75M	$242,000 0.0% of portfolio	192,500	Q3 2025 Added 7.72%
IMAB I Mab	$355M	$240,000 0.0% of portfolio	63,600	Q3 2025 Reduced 0.16%
IMRX Immuneering Corp	$169M	$229,000 0.0% of portfolio	35,000	Q3 2025 Added 92.31%
VACC Vaccitech PLC	$127M	$226,000 0.0% of portfolio	66,300	Q3 2025 Added 82.64%
GANX Gain Therapeutics, Inc.	$33.6M	$223,000 0.0% of portfolio	126,100	Q3 2025 Added 34.15%
BLTE Belite Bio, Inc	$2.9B	$208,000 0.0% of portfolio	2,812	Q3 2025 Reduced 34.6%
XENE Xenon Pharmaceuticals Inc.	$2.49B	$208,000 0.0% of portfolio	5,200	Q3 2025 Reduced 39.53%
CRDF Cardiff Oncology, Inc.	$93.2M	$205,000 0.0% of portfolio	101,800	Q3 2025 Reduced 21.51%
IOBT Io Biotech, Inc.	$23.6M	$197,000 0.0% of portfolio	547,315	Q3 2025 Added 292.9%
DYAI Dyadic International Inc	$26.1M	$196,000 0.0% of portfolio	165,100	Q3 2025 Added 246.81%
XLO Xilio Therapeutics, Inc.	$19.2M	$173,000 0.0% of portfolio	204,700	Q3 2025 Added 24.67%
ORIC Oric Pharmaceuticals, Inc.	$518M	$172,000 0.0% of portfolio	14,500	Q3 2025 Added 42.16%
OCUP Ocuphire Pharma, Inc.	$20.2M	$170,000 0.0% of portfolio	173,809	Q3 2025 Added 13.37%
ENTX Entera Bio Ltd.	$78.1M	$168,000 0.0% of portfolio	88,400	Q3 2025 Added 37.48%
ENLV Enlivex Therapeutics Ltd.	$18M	$160,000 0.0% of portfolio	157,292	Q3 2025 Reduced 6.59%
CUE Cue Biopharma, Inc.	$22.3M	$158,000 0.0% of portfolio	227,064	Q3 2025 Added 70.13%
ANIX Anixa Biosciences Inc	$127M	$141,000 0.0% of portfolio	42,764	Q3 2025 Added 54.53%
SCPH Sc Pharmaceuticals Inc.	$155M	$131,000 0.0% of portfolio	23,216	Q3 2025 New
ARMP Armata Pharmaceuticals, Inc.	$254M	$125,000 0.0% of portfolio	41,296	Q3 2025 Added 6.17%

Shares Options

Jim Simons

Jim Simons is the founder and chairman of Renaissance Technologies, a successful investment firm that uses quantitative approaches to investing. Simons is known for his expertise in mathematical modeling and has a reputation for being a skilled and successful investor. He has generated strong returns for his clients over the long term.

Track Jim Simons's portfolio

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account